Aptose Biosciences’ (APTO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research note on Sunday. They set a “hold” rating for the company.

Aptose Biosciences Price Performance

APTO stock opened at $0.23 on Wednesday. The business has a 50 day simple moving average of $0.21 and a 200-day simple moving average of $0.32. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.12.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.